Managers / Q3 2024 · view latest →
Medicxi Ventures Management (Jersey) Ltd
CIK 0001715579 · C/O CSC FUND SERVICES (JERSEY) LIMITED, 44 ESPLANADE, ST. HELIER, Y9, JE4 9WG · 44 (0) 1534 504343
Summary
Medicxi Ventures Management (Jersey) Ltd reported $529M in U.S.-listed holdings across 4 positions for Q3 2024.
The portfolio is heavily concentrated: 260 alone accounts for 60.4% of reported value.
The book was largely unchanged from Q2 2024.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- ADR · 60.4% · $319M
- Common Stock · 30.6% · $162M
- Other · 9.0% · $48M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| 260CENTESSA PHARMACEUTICALS PLC | HELD | +0 | 19.96M | +$139M | $319M |
| PHATPHATHOM PHARMACEUTICALS INC | HELD | +0 | 7.46M | +$58M | $135M |
| NEWAMSTERDAM PHARMA COMPANY | HELD | +0 | 2.87M | −$7M | $48M |
| AURAAURA BIOSCIENCES INC | HELD | +0 | 3.04M | +$4M | $27M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | 260CENTESSA PHARMACEUTICALS PLChistory → | SPONSORED ADS | 60.35% | $319M | 19.96M |
| 2 | PHATPHATHOM PHARMACEUTICALS INChistory → | COM | 25.52% | $135M | 7.46M |
| 3 | NEWAMSTERDAM PHARMA COMPANY | ORDINARY SHARES | 9.01% | $48M | 2.87M |
| 4 | AURAAURA BIOSCIENCES INChistory → | COM | 5.12% | $27M | 3.04M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $982M | 4 | Apr 21, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $835M | 5 | Jan 23, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $744M | 5 | Oct 17, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $427M | 5 | Jul 8, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $438M | 5 | Apr 11, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $529M | 5 | Jan 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $529M | 4 | Oct 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $335M | 4 | Jul 16, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $449M | 5 | Apr 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $296M | 5 | Feb 1, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $313M | 6 | Oct 18, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $357M | 6 | Jul 19, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $233M | 6 | Apr 27, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $238M | 6 | Jan 31, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $240M | 6 | Oct 25, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $241M | 7 | Aug 3, 2022 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2022 | $369M | 7 | May 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $400M | 7 | Feb 3, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $460M | 6 | Nov 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $558M | 6 | Aug 3, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $172M | 5 | May 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $172M | 5 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $209M | 5 | Oct 27, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $163M | 4 | Aug 7, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $77M | 3 | May 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $163M | 4 | Feb 11, 2020 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- Francesco De Rubertis028-19836
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.